Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Up 8.3% in September

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the target of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 2,490,000 shares, an increase of 8.3% from the September 15th total of 2,300,000 shares. Based on an average trading volume of 423,800 shares, the short-interest ratio is currently 5.9 days. Approximately 2.9% of the company’s shares are short sold.

Analysts Set New Price Targets

A number of research firms have issued reports on CMPX. LADENBURG THALM/SH SH raised Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Monday, September 16th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a report on Monday, August 12th. Finally, Wedbush restated an “outperform” rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, August 7th.

Compass Therapeutics Trading Down 4.0 %

Compass Therapeutics stock traded down $0.08 during midday trading on Thursday, reaching $1.90. 2,167,736 shares of the stock traded hands, compared to its average volume of 431,754. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $2.34. The firm has a market cap of $261.42 million, a price-to-earnings ratio of -5.24 and a beta of 0.90. The firm has a fifty day moving average price of $1.55 and a two-hundred day moving average price of $1.39.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Monday, August 12th. The company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). The business had revenue of $0.85 million for the quarter. Analysts anticipate that Compass Therapeutics will post -0.42 earnings per share for the current year.

Hedge Funds Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CMPX. Cubist Systematic Strategies LLC purchased a new position in Compass Therapeutics during the 2nd quarter valued at about $41,000. Panagora Asset Management Inc. acquired a new position in Compass Therapeutics in the 2nd quarter valued at approximately $68,000. SG Americas Securities LLC lifted its position in Compass Therapeutics by 16.6% in the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock worth $71,000 after buying an additional 5,515 shares in the last quarter. Bleakley Financial Group LLC purchased a new stake in Compass Therapeutics in the 1st quarter worth approximately $80,000. Finally, Ground Swell Capital LLC purchased a new position in shares of Compass Therapeutics during the 2nd quarter valued at $124,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.